Fundz

Ophirex, Inc. reported raising in an initial SEC Form D filing, from an offering of $5 Million

PRIVATEMar 29, 2019$0 of $5M raised

Round Type

Venture

Corte MaderaOtherBiotechnology

Who else raised in Biotechnology around the same time

Companies in the same sectors as Ophirex, Inc. that raised within 45 days of this round, from Fundz verified event records.

  • Nature's Toolbox raised $915K (Seed) on May 13, 2019.
  • Eledon raised $862K (Seed) on May 10, 2019.
  • Neuralink raised $323M on May 10, 2019.
  • Route 92 Medical raised $13M on May 10, 2019.
  • MBX Biosciences, Inc. raised $23M on May 10, 2019.
  • Phylos raised $2M on May 10, 2019.

Who to call at Ophirex, Inc., and when

A new round usually means Ophirex, Inc. is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Ophirex, Inc. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Ophirex, Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Ophirex, Inc.. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Ophirex, Inc.

Location

5643 PARADISE DR STE 2

Corte Madera, California, United States

About

Ophirex is a Public Benefit Corporation developing a first-of-its-kind oral treatment to address the global unmet need of venomous snakebites. Worldwide, there are approximately 500,000 cases of snakebite envenoming resulting in death or permanent disability each year. While antivenom has been the standard of care to treat these bites for more than 100 years, it can only be administered in a hospital setting. This poses a significant challenge as 75% of deaths from venomous snakebites occur before the victim can reach appropriately equipped medical care. Ophirex is advancing its investigational treatment, varespladib, as an easily portable, oral, broad-spectrum treatment for snakebite. Ideally taken immediately following a snake’s bite, it is intended to provide a bridge to survival between bite and arrival to the hospital. If successful, this early intervention is anticipated to result in improved overall outcomes for patients at risk of death and long-term disability from snakebite. The company previously completed a Phase 2 clinical study of the varespladib oral formulation and is currently enrolling patients in a Phase 2 study to evaluate IV-to-oral dosing.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Ophirex, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contacts4 people are listed at Ophirex, Inc.. We don't have their email yet.See plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Ophirex, Inc.'s next move

See what Strategic adds

Ophirex, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.